Biotech Company Named In Securities Suit Over COVID-19 Blood Test Misstatements
LOS ANGELES — A biotechnology company and its CEO violated federal securities law by misrepresenting to investors that the company had developed a rapid-result finger-prick blood test for the detection of...To view the full article, register now.
Already a subscriber? Click here to view full article